Replies to post #218167 on Innovation Pharmaceuticals Inc (IPIX)

[Rdunn88]

No expectations for P? Leo shifted IPIX strategy (Dr B) to focus on their dermatology candidates away from the high costs of K/Absssi. If P fails before B deal I’m not sure how the stock survives with K being a disappointment. They’ll be down from big 3 to 1...,

[rmzport]

Daubers....and we should add, from the 5/26/16 pr (Prurisol ph 2a)

"As previously released, the trial achieved its primary endpoint in patients treated with 200mg of oral Prurisol. Among patients participating in the study with the severest form of psoriasis, those having a baseline IGA score of 3 (“moderate”), the primary endpoint was met in 46.2% of patients who received Prurisol 200mg. This data was derived from analyses of all patients randomized across all 9 participating study sites.

Additional preliminary data analyses of secondary endpoints show patients who received any dose of Prurisol, regardless of the treatment arm, had a 1-point improvement (using the IGA scoring system) at a higher rate than that of patients in the placebo arm. This is another clear indication of the drug’s efficacy. Increases in Prurisol’s therapeutic response, upon evaluating patients at Day 56 (Week 8) and Day 84 (Week 12) of treatment, also were apparent in the Prurisol 200mg arm, suggesting an improving response over time."